\-\ Texto\\:\\ \ \(0\)\
\-\ external\\ examination\\:\\ bilateral\\ superotemporal\\ firm\\,\\ non\\-mobile\\ subconjunctival\\ masses\\ with\\ dilated\\ vasculature\\;\\ 3\\.5\\ mm\\ right\\ proptosis\\;\\ full\\ ductions\\,\\ no\\ diplopia\ \(0\)\
\-\ internal\\ examination\\:\\ 2\\-3\\+\\ nuclear\\ sclerotic\\ cataracts\\ o\\.u\\.\\ resulting\\ in\\ 20\\/40\\ \\â\\€\\“\\ 20\\/50\\ best\\ corrected\\ va\\;\\ choroidal\\ nevus\\,\\ unchanged\\ for\\ 15\\ years\ \(0\)\
\-\ may\\ 2004\\:\ \(0\)\
\-\ rx\\:\\ thalidomide\ \(0\)\
\-\ shrinkage\\ of\\ orbital\\ masses\ \(0\)\
\-\ march\\ 2005\\:\ \(0\)\
\-\ clinical\\ examination\\:\\ recurrence\\ right\\ orbit\ \(0\)\
\-\ rx\\:\\ liposomal\\ vincristine\ \(0\)\
\-\ november\\ 2005\\:\ \(0\)\
\-\ no\\ evidence\\ of\\ orbital\\ disease\ \(0\)\
\-\ biopsies\\ of\\ right\\ orbital\\ lobe\\ of\\ lacrimal\\ gland\\ and\\ right\\ subconjunctival\\ mass\\.\ \(0\)\
\-\ histopathology\\:\\ monomorphous\\ centrocyte\\-like\\ small\\ lymphocytes\\,\\ cyclin\\ d1\\ \\+\\ \\[ihc\\]\ \(0\)\
\-\ flow\\ cytometry\\:\\ cd5\\/cd20\\ \\+\\,cd10\\,\\ cd23\\ \\â\\€\\“\\,\\ fmc7\\ \\+\ \(0\)\
\-\ cytogenetics\\:\\ t\\(11\\;14\\)\\(q12\\-13\\.1\\;q32\\)\ \(0\)\
\-\ mantle\\ cell\\ lymphoma\ \(1\)\
\-\ 70\\-year\\-old\\ female\\ with\\ \\â\\€\\˜swollen\\ eyelids\\â\\€\\™\\ and\\ pain\\ on\\ abduction\\ of\\ right\\ eye\\ x\\ 4\\ days\\.\ \(1\)\
\-\ remote\\ history\\ of\\ breast\\ \\(age\\ 46\\)\\ and\\ ovarian\\ \\(age\\ 28\\)\\ cancer\\.\ \(0\)\
\-\ 1999\\:\\ mantle\\ cell\\ lymphoma\\,\\ periaortic\\ lymph\\ nodes\\/ileocecal\\ valve\\/bone\\ marrow\\:\\ chop\\,\\ hyper\\ cvad\\.\\ autologous\\ stem\\ cell\\ transplant\\ 2002\\.\\ no\\ chemotherapy\\ since\\ january\\ 2004\ \(0\)\
\-\ recently\\ defined\\ category\\ of\\ b\\-cell\\ lymphomas\\ \\(3\\-10\\%\\)\\.\ \(0\)\
\-\ clinical\\ features\\:\ \(0\)\
\-\ late\\ adulthood\\ \\(median\\ age\\ 60\\)\ \(0\)\
\-\ male\\ predominance\ \(11\)\
\-\ multifocal\\ lymphadenopathy\\,\\ hepatosplenomegaly\\,\\ bone\\ marrow\\ involvement\ \(0\)\
\-\ gi\\ tract\\,\\ waldeyer\\â\\€\\™s\\ ring\\ also\\ common\\ extranodal\\ sites\ \(0\)\
\-\ median\\ survival\\ 3\\-5\\ years\ \(0\)\
\-\ cell\\ of\\ origin\\:\\ \\â\\€\\˜mantle\\ cell\\â\\€\\™\\ immediately\\ surrounding\\ follicle\\:\ \(0\)\
\-\ \\â\\€\\˜centrocyte\\-like\\â\\€\\™\\ morphology\ \(0\)\
\-\ proliferative\\ in\\ monotonous\\ sheets\\ of\\ small\\ cells\\ with\\ irregular\\ nuclear\\ contours\\,\\ inconspicuous\\ nucleoli\ \(0\)\
\-\ hyalinized\\ capillaries\ \(0\)\
\-\ immunophenotype\\:\ \(0\)\
\-\ b\\-cell\\ lymphocyte\ \(0\)\
\-\ cd19\\+\\,\\ cd20\\+\ \(0\)\
\-\ coexpression\\ of\\ cd5\\ \\(cd5\\+\\/cd20\\+\\)\ \(0\)\
\-\ ddx\\:\\ sll\\/cll\ \(0\)\
\-\ negative\\ for\\:\ \(0\)\
\-\ cd23\\ \\(cll\\/sll\\ cd5\\+\\,cd23\\+\\)\ \(0\)\
\-\ cd10\\ \\(fl\\ cd5\\-\\,cd10\\+\\)\\;\\ \\(malt\\ cd5\\-\\,cd10\\-\\)\ \(0\)\
\-\ cyclin\\ d1\\+\\,\\ fmc7\\+\ \(0\)\
\-\ cytogenetics\\:\ \(0\)\
\-\ t\\(11\\;14\\)\\ \\(q13\\;q32\\)\ \(1\)\
\-\ juxtaposition\\ of\\ ig\\ heavy\\ chain\\ promoter\\ and\\ cyclin\\ d1\\ gene\ \(0\)\
\-\ overexpression\\ of\\ cyclin\\ d1\\ gene\\,\\ increased\\ mrna\\,\\ gene\\ product\ \(0\)\
\-\ promotes\\ phosphorylation\\ of\\ prb\\,\\ passage\\ of\\ cell\\ into\\ s\\ phase\ \(0\)\
\-\ ocular\\ adnexal\\ involvement\\:\ \(0\)\
\-\ rare\\:\\ eyelid\\,\\ conjunctiva\\,\\ orbit\\,\\ lacrimal\\ gland\ \(0\)\
\-\ 3\\-5\\%\\ of\\ all\\ ocular\\ adnexal\\ lymphomas\ \(1\)\
\-\ demographics\ \(7\)\
\-\ age\\ \\>\\ 60\ \(0\)\
\-\ m\\ \\>\\>\\ f\ \(0\)\
\-\ aggressive\\ behavior\ \(0\)\
\-\ median\\ survival\\ \\<\\ 5\\ years\ \(0\)\
\-\ largest\\ series\\:\\ white\\,\\ rootman\\ et\\ al\ \(0\)\
\-\ 10\\ cases\\:\\ \ \(1\)\
\-\ 9\\ with\\ multiple\\ periocular\\ sites\ \(1\)\
\-\ 6\\ bilateral\ \(1\)\
\-\ 9\\ orbital\\,\\ 5\\ lacrimal\\ gland\\,\\ 5\\ eyelid\ \(1\)\
\-\ 8\\ periocular\\ presenting\\ site\ \(1\)\
\-\ unusual\\ findings\ \(1\)\
\-\ 3\\ cases\\ cd5\\ \\â\\€\\“\ \(0\)\
\-\ 2\\ cases\\ composite\\ lymphomas\ \(1\)\
\-\ mantle\\ cell\\/follicular\\ lymphoma\ \(0\)\
\-\ mantle\\ cell\\/plasma\\ cell\\ neoplasm\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cyclin\\:\\ 0\\.07888607090797761\ \(0\)\
\-\ mantle\\:\\ 0\\.07534761613296043\ \(0\)\
\-\ \\:\\:\\ 0\\.06068589616057262\ \(0\)\
\-\ d1\\:\\ 0\\.05451255868058089\ \(0\)\
\-\ \\â\\€\\˜\\:\\ 0\\.04371096195283525\ \(0\)\
\-\ lymphomas\\:\\ 0\\.04371096195283525\ \(0\)\
\-\ subconjunctival\\:\\ 0\\.039443035453988806\ \(0\)\
\-\ centrocyte\\-like\\:\\ 0\\.039443035453988806\ \(0\)\
\-\ q32\\:\\ 0\\.039443035453988806\ \(0\)\
\-\ cd5\\-\\:\\ 0\\.039443035453988806\ \(0\)\
\-\ periocular\\:\\ 0\\.039443035453988806\ \(0\)\
\-\ lacrimal\\:\\ 0\\.03905896745243293\ \(0\)\
\-\ gene\\:\\ 0\\.03841930181616229\ \(0\)\
\-\ cd23\\:\\ 0\\.036341705787053924\ \(0\)\
\-\ cytogenetics\\:\\ 0\\.036341705787053924\ \(0\)\
\-\ orbital\\:\\ 0\\.03627153905296413\ \(0\)\
\-\ \\;\\:\\ 0\\.0362491487866236\ \(0\)\
\-\ cell\\:\\ 0\\.036146946266376746\ \(0\)\
\-\ cd5\\:\\ 0\\.03324037612011905\ \(0\)\
\-\ median\\:\\ 0\\.03318333834267522\ \(0\)\
\-\ cd10\\:\\ 0\\.03224197096882504\ \(0\)\
\-\ \\+\\:\\ 0\\.029589256219478152\ \(0\)\
\-\ rx\\:\\ 0\\.028324884895653234\ \(0\)\
\-\ 3\\-5\\:\\ 0\\.027635172681661026\ \(0\)\
\-\ eyelid\\:\\ 0\\.027326479744359228\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.025810101505976492\ \(0\)\
\-\ gland\\:\\ 0\\.02442529323082328\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.023798706319910594\ \(0\)\
\-\ age\\:\\ 0\\.023274365329255538\ \(0\)\
\-\ ocular\\:\\ 0\\.023167482166622427\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.022854825410697593\ \(0\)\
\-\ adnexal\\:\\ 0\\.021123820410489477\ \(0\)\
\-\ sites\\:\\ 0\\.020835057452379534\ \(0\)\
\-\ 2005\\:\\ 0\\.02063009308534914\ \(0\)\
\-\ 2004\\:\\ 0\\.020563806348055443\ \(0\)\
\-\ survival\\:\\ 0\\.020498487334985407\ \(0\)\
\-\ nuclear\\:\\ 0\\.019726170812985437\ \(0\)\
\-\ superotemporal\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ ductions\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ 2\\-3\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ o\\.u\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ ihc\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd5\\/cd20\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ fmc7\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ q12\\-13\\.1\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ nodes\\/ileocecal\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ valve\\/bone\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cvad\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ waldeyer\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ monotonous\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ immunophenotype\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd20\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ coexpression\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd5\\+\\/cd20\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cll\\/sll\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd5\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd23\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cd10\\-\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ d1\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ fmc7\\+\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ q13\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ mrna\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ phosphorylation\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ prb\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cell\\/follicular\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ cell\\/plasma\\:\\ 0\\.019721517726994403\ \(0\)\
\-\ \\(\\:\\ 0\\.019392261107217732\ \(0\)\
\-\ orbit\\:\\ 0\\.019260218870020798\ \(0\)\
\-\ \\)\\:\\ 0\\.01915537428492094\ \(0\)\
\-\ cases\\:\\ 0\\.019106113181081425\ \(0\)\
\-\ \\>\\:\\ 0\\.019054815534688352\ \(0\)\
\-\ 20\\/50\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ thalidomide\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ liposomal\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ 70\\-year\\-old\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ cd19\\+\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ sll\\/cll\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ cd10\\+\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ juxtaposition\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ promoter\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ overexpression\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ promotes\\:\\ 0\\.018170852893526962\ \(0\)\
\-\ examination\\:\\ 0\\.017828342519963524\ \(0\)\
\-\ t\\:\\ 0\\.01769890836512226\ \(0\)\
\-\ 11\\:\\ 0\\.0174954972954276\ \(0\)\
\-\ shrinkage\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ monomorphous\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ 3\\-10\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ extranodal\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ rootman\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ composite\\:\\ 0\\.017263772114761496\ \(0\)\
\-\ 14\\:\\ 0\\.016848601417078127\ \(0\)\
\-\ years\\:\\ 0\\.016840557966566996\ \(0\)\
\-\ marrow\\:\\ 0\\.016820011716412484\ \(0\)\
\-\ 5\\:\\ 0\\.016779600150631967\ \(0\)\
\-\ 60\\:\\ 0\\.016679740889190667\ \(0\)\
\-\ cataracts\\:\\ 0\\.016620188060059524\ \(0\)\
\-\ follicle\\:\\ 0\\.016620188060059524\ \(0\)\
\-\ inconspicuous\\:\\ 0\\.016620188060059524\ \(0\)\
\-\ hyalinized\\:\\ 0\\.016620188060059524\ \(0\)\
\-\ malt\\:\\ 0\\.016620188060059524\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0163905948616744\ \(0\)\
\-\ \\,\\:\\ 0\\.016351614695675077\ \(0\)\
\-\ 20\\/40\\:\\ 0\\.01612098548441252\ \(0\)\
\-\ chop\\:\\ 0\\.01612098548441252\ \(0\)\
\-\ 9\\:\\ 0\\.01580454002339378\ \(0\)\
\-\ sheets\\:\\ 0\\.015713107281294054\ \(0\)\
\-\ ig\\:\\ 0\\.015713107281294054\ \(0\)\
\-\ cytometry\\:\\ 0\\.015368251174297952\ \(0\)\
\-\ eyelids\\:\\ 0\\.015069523226592085\ \(0\)\
\-\ periaortic\\:\\ 0\\.015069523226592085\ \(0\)\
\-\ nucleoli\\:\\ 0\\.015069523226592085\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.014806026502528586\ \(0\)\
\-\ fl\\:\\ 0\\.014806026502528586\ \(0\)\
\-\ va\\:\\ 0\\.014570320650945084\ \(0\)\
\-\ capillaries\\:\\ 0\\.014570320650945084\ \(0\)\
\-\ proliferative\\:\\ 0\\.014357098772188204\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.014357098772188204\ \(0\)\
\-\ autologous\\:\\ 0\\.014162442447826617\ \(0\)\
\-\ involvement\\:\\ 0\\.01401314835180231\ \(0\)\
\-\ non\\-mobile\\:\\ 0\\.013983375987706848\ \(0\)\
\-\ 2002\\.\\:\\ 0\\.013817586340830513\ \(0\)\
\-\ demographics\\:\\ 0\\.013817586340830513\ \(0\)\
\-\ behavior\\:\\ 0\\.013817586340830513\ \(0\)\
\-\ hyper\\:\\ 0\\.013663239872179614\ \(0\)\
\-\ november\\:\\ 0\\.013518858393124646\ \(0\)\
\-\ choroidal\\:\\ 0\\.0133832328409626\ \(0\)\
\-\ corrected\\:\\ 0\\.013255361669061149\ \(0\)\
\-\ contours\\:\\ 0\\.013255361669061149\ \(0\)\
\-\ product\\:\\ 0\\.013255361669061149\ \(0\)\
\-\ nevus\\:\\ 0\\.013134405916778653\ \(0\)\
\-\ january\\:\\ 0\\.013019655817477644\ \(0\)\
\-\ masses\\:\\ 0\\.01292435077403171\ \(0\)\
\-\ vincristine\\:\\ 0\\.012910505562065045\ \(0\)\
\-\ chain\\:\\ 0\\.012910505562065045\ \(0\)\
\-\ adulthood\\:\\ 0\\.012806433938720765\ \(0\)\
\-\ hepatosplenomegaly\\:\\ 0\\.012611777614359177\ \(0\)\
\-\ category\\:\\ 0\\.012520453241830643\ \(0\)\
\-\ heavy\\:\\ 0\\.012520453241830643\ \(0\)\
\-\ march\\:\\ 0\\.01234828089029568\ \(0\)\
\-\ biopsies\\:\\ 0\\.01234828089029568\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.01234828089029568\ \(0\)\
\-\ abduction\\:\\ 0\\.012266921507363074\ \(0\)\
\-\ unchanged\\:\\ 0\\.012039219730383337\ \(0\)\
\-\ predominance\\:\\ 0\\.011968193559657206\ \(0\)\
\-\ passage\\:\\ 0\\.011899353159955297\ \(0\)\
\-\ clinical\\:\\ 0\\.01176424966472485\ \(0\)\
\-\ morphology\\:\\ 0\\.011413750239960158\ \(0\)\
\-\ stem\\:\\ 0\\.011359840728597605\ \(0\)\
\-\ 3\\.5\\:\\ 0\\.011156324446258173\ \(0\)\
\-\ diplopia\\:\\ 0\\.011156324446258173\ \(0\)\
\-\ remote\\:\\ 0\\.01106111278089174\ \(0\)\
\-\ s\\:\\ 0\\.010965403432280032\ \(0\)\
\-\ 1999\\:\\ 0\\.010839432909204421\ \(0\)\
\-\ largest\\:\\ 0\\.010839432909204421\ \(0\)\
\-\ proptosis\\:\\ 0\\.010676660304545746\ \(0\)\
\-\ histopathology\\:\\ 0\\.010676660304545746\ \(0\)\
\-\ transplant\\:\\ 0\\.010561910205244739\ \(0\)\
\-\ vasculature\\:\\ 0\\.010382843745124968\ \(0\)\
\-\ multifocal\\:\\ 0\\.010281903174027721\ \(0\)\
\-\ swollen\\:\\ 0\\.010185321134060812\ \(0\)\
\-\ 46\\:\\ 0\\.010123174458206057\ \(0\)\
\-\ ddx\\:\\ 0\\.010092736757857558\ \(0\)\
\-\ right\\:\\ 0\\.010085365873718308\ \(0\)\
\-\ \\]\\:\\ 0\\.010003832219491754\ \(0\)\
\-\ \\[\\:\\ 0\\.009974965542006503\ \(0\)\
\-\ f\\:\\ 0\\.009974965542006503\ \(0\)\
\-\ late\\:\\ 0\\.009946466602907107\ \(0\)\
\-\ m\\:\\ 0\\.009863085406492719\ \(0\)\
\-\ series\\:\\ 0\\.0095104479474243\ \(0\)\
\-\ immediately\\:\\ 0\\.009487264978664688\ \(0\)\
\-\ firm\\:\\ 0\\.009374822395262251\ \(0\)\
\-\ aggressive\\:\\ 0\\.009352996500529894\ \(0\)\
\-\ bilateral\\:\\ 0\\.009278826529371113\ \(0\)\
\-\ unusual\\:\\ 0\\.009246951223360802\ \(0\)\
\-\ 28\\:\\ 0\\.0090112453717773\ \(0\)\
\-\ phase\\:\\ 0\\.008992679817382006\ \(0\)\
\-\ recently\\:\\ 0\\.008919920999248763\ \(0\)\
\-\ \\%\\:\\ 0\\.008918662341592875\ \(0\)\
\-\ ring\\:\\ 0\\.0088844101510244\ \(0\)\
\-\ small\\:\\ 0\\.008807943106850642\ \(0\)\
\-\ origin\\:\\ 0\\.008764381709207129\ \(0\)\
\-\ ovarian\\:\\ 0\\.0087477486477138\ \(0\)\
\-\ gi\\:\\ 0\\.008587885193615042\ \(0\)\
\-\ sclerotic\\:\\ 0\\.008557239009368594\ \(0\)\
\-\ tract\\:\\ 0\\.008467741616496783\ \(0\)\
\-\ resulting\\:\\ 0\\.008395801769439668\ \(0\)\
\-\ recurrence\\:\\ 0\\.008339870444595334\ \(0\)\
\-\ full\\:\\ 0\\.008258511061662727\ \(0\)\
\-\ external\\:\\ 0\\.008129160791217926\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.008129160791217926\ \(0\)\
\-\ al\\:\\ 0\\.00810416459301183\ \(0\)\
\-\ site\\:\\ 0\\.00807944460154296\ \(0\)\
\-\ features\\:\\ 0\\.00806718628887042\ \(0\)\
\-\ defined\\:\\ 0\\.008054994779323294\ \(0\)\
\-\ best\\:\\ 0\\.008042869348743117\ \(0\)\
\-\ eye\\:\\ 0\\.008018813886156401\ \(0\)\
\-\ et\\:\\ 0\\.007824157561794814\ \(0\)\
\-\ presenting\\:\\ 0\\.007791498055259797\ \(0\)\
\-\ lymph\\:\\ 0\\.00771709711173299\ \(0\)\
\-\ cells\\:\\ 0\\.0076654288459731485\ \(0\)\
\-\ 15\\:\\ 0\\.007624936582788321\ \(0\)\
\-\ irregular\\:\\ 0\\.007624936582788321\ \(0\)\
\-\ rare\\:\\ 0\\.007423602234168447\ \(0\)\
\-\ \\<\\:\\ 0\\.007378222656603558\ \(0\)\
\-\ 8\\:\\ 0\\.007147914000557826\ \(0\)\
\-\ breast\\:\\ 0\\.007052702335191392\ \(0\)\
\-\ mm\\:\\ 0\\.00702951936643178\ \(0\)\
\-\ since\\:\\ 0\\.007021844791271178\ \(0\)\
\-\ dilated\\:\\ 0\\.006946513213851518\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.006852227707250257\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0065104173957761255\ \(0\)\
\-\ 10\\:\\ 0\\.00644434950413179\ \(0\)\
\-\ internal\\:\\ 0\\.006409118280489422\ \(0\)\
\-\ white\\:\\ 0\\.006340277880787512\ \(0\)\
\-\ flow\\:\\ 0\\.0063177939079608865\ \(0\)\
\-\ x\\:\\ 0\\.006306636096974222\ \(0\)\
\-\ cancer\\:\\ 0\\.006284486050033032\ \(0\)\
\-\ surrounding\\:\\ 0\\.006284486050033032\ \(0\)\
\-\ days\\:\\ 0\\.005859226613360129\ \(0\)\
\-\ no\\:\\ 0\\.005774792957743637\ \(0\)\
\-\ negative\\:\\ 0\\.005709441076901285\ \(0\)\
\-\ 6\\:\\ 0\\.005709441076901285\ \(0\)\
\-\ all\\:\\ 0\\.005406987672105796\ \(0\)\
\-\ 4\\:\\ 0\\.0053265590719889155\ \(0\)\
\-\ lobe\\:\\ 0\\.0051439045814844165\ \(0\)\
\-\ evidence\\:\\ 0\\.00501217580171561\ \(0\)\
\-\ common\\:\\ 0\\.005002834926076951\ \(0\)\
\-\ bone\\:\\ 0\\.004750413157628345\ \(0\)\
\-\ increased\\:\\ 0\\.004676699735569699\ \(0\)\
\-\ into\\:\\ 0\\.004548828563668248\ \(0\)\
\-\ 3\\:\\ 0\\.0044764553170168675\ \(0\)\
\-\ may\\:\\ 0\\.0041931283420539684\ \(0\)\
\-\ 2\\:\\ 0\\.00411656486915111\ \(0\)\
\-\ findings\\:\\ 0\\.004068986433534585\ \(0\)\
\-\ multiple\\:\\ 0\\.004026411640893219\ \(0\)\
\-\ female\\:\\ 0\\.003930112464089113\ \(0\)\
\-\ of\\:\\ 0\\.003909523516711021\ \(0\)\
\-\ also\\:\\ 0\\.003768723923199444\ \(0\)\
\-\ male\\:\\ 0\\.0034568356552292464\ \(0\)\
\-\ for\\:\\ 0\\.00326222885298754\ \(0\)\
\-\ disease\\:\\ 0\\.0031246924859411724\ \(0\)\
\-\ mass\\:\\ 0\\.0026587494562585337\ \(0\)\
\-\ history\\:\\ 0\\.0026403009792104774\ \(0\)\
\-\ pain\\:\\ 0\\.0023346938870933663\ \(0\)\
\-\ in\\:\\ 0\\.0018854462198669125\ \(0\)\
\-\ on\\:\\ 0\\.0016194429806832842\ \(0\)\
\-\ and\\:\\ 0\\.0016108188432413283\ \(0\)\
\-\ with\\:\\ 0\\.0010470172357037112\ \(0\)\
\-\ \\.\\:\\ 0\\.0004765038402328359\ \(0\)\
